| Outcome Measures: |
Primary: The maximum plasma concentration (Cmax) of SHR3824., Cmax (a measure of the body's exposure to SHR3824) will be compared before and after administration of a single dose of metformin., At protocol-specified times up to Day 9.|The area under the plasma concentration-time curve (AUC) of SHR3824., AUC (a measure of the body's exposure to SHR3824) will be compared before and after administration of a single dose of metformin., At protocol-specified times up to Day 9.|The maximum plasma concentration (Cmax) of metformin., Cmax (a measure of the body's exposure to metformin) will be compared. before and after administration of multiple doses of SHR3824, At protocol-specified times up to Day 9.|The area under the plasma concentration-time curve (AUC) of metformin, AUC (a measure of the body's exposure to metformin) will be compared before and after administration of multiple doses of SHR3824., At protocol-specified times up to Day 9. | Secondary: The number of volunteers with adverse events as a measure of safety and tolerability., Up tp day 9.
|
